Dilshat Djumanov MPhil, PhD

Dilshat has an in depth knowledge of data management and data analysis for adaptive clinical trials and QTc studies. Dilshat has a background in IT and demonstrable knowledge of process automation and improvement.

Having worked at Richmond Pharmacology for 14 years, he has led pioneering software development projects which have ensured Richmond Pharmacology’s data management and other processes are efficient, transparent and fast.

Dilshat’s experience is backed by his academic achievements, including a MSc in Computer Sciences, a MPhil in Medical Engineering and a PhD in Computational Fluid Dynamics.

Back to experts

More about us Adaptive Phase I & IIa Bridging Studies TQT Studies Patient Recruitment

Meet the experts

Richmond Pharmacology has a team of experts with extensive knowledge of clinical research trials.

Latest Publications

View our latest peer-reviewed publications from a selection of our clinical trials.

Latest Videos

Learn more about Richmond Pharmacology by viewing some of our videos.

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020

Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.

View event

COVID-19 – External Monitoring Guidelines

July 1, 2020

Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.

First transdermal patch to treat schizophrenia hits market

March 18, 2020

The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful

Statement: COVID-19

March 23, 2020

Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.

World-classScientific Advisory